EUVIMEDEUVIMED entdecken
Klinische Studie

Timed sequential chemotherapy for advanced acute myeloid leukemia

E Archimbaud, V Leblond, P Fenaux, H Dombret, C Cordonnier, F Dreyfus, P Cony-Makhoul, H Tilly, X Troussard, G Auzanneau, X Thomas, M Ffrench und 1 weitere

Hematology and Cell Therapy · 1996

DOI: 10.1007/s00282-996-0161-2 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Hematology and Cell Therapy, 1996. Verfasst von E Archimbaud und 12 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France. Die Arbeit wurde bisher 13-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Timed sequential chemotherapy (TSC) combining mitoxantrone on days 1-3, etoposide on days 8-10 and cytarabine on days 1-3 and 8-10, was administered to 240 patients with advanced acute myelogenous leukemia (AML). Sixty one percent of patients, with a 95% confidence interval (CI) ranging from 54 to 67%, achieved complete remission (CR), including 47% (CI: 38-55%) of refractory patients and 78% (CI: 70-86%) of late first relapse patients (p < 0.0001). Thirty percent of patients did not respond to therapy and 9% died from toxicity. Median duration of neutropenia was 32 days and of thrombocytopenia 29 days. Severe non hematologic toxicity included sepsis in 45% of patients and mucositis in 27%. Post-remission therapy varied but included maintenance chemotherapy in most patients, a second course of TSC in 27, autologous stem cell transplantation in 17 and allogeneic transplantation in 20. Median survival of patients who were not transplanted was 7 months with 13% (CI: 7-19%) survival at 5 years. Median disease-free survival (DFS) was 9 months with 13% (CI: 6-20%) DFS at 5 years. Previous refractoriness was the main factor associated with poor prognosis for achieving CR, DFS and survival in a multivariate analysis. There was no difference in DFS between patients receiving the different modalities of intensive post-remission therapy. These results confirm initial reports on TSC and show that some patients with first relapse off therapy can enjoy prolonged DFS using chemotherapy only.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute DiseaseAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCytarabineDaunorubicinEtoposideFemaleGranulocyte-Macrophage Colony-Stimulating FactorHumansLeukemia, MyeloidMaleMiddle AgedMitoxantrone

Substanzen

CytarabineEtoposideGranulocyte-Macrophage Colony-Stimulating FactorMitoxantroneDaunorubicin

Autor:innen und Institutionen

  • Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France.

Zitieren

APA

Archimbaud, E., Leblond, V., Fenaux, P., Dombret, H., Cordonnier, C., Dreyfus, F., Cony-Makhoul, P., Tilly, H., Troussard, X., Auzanneau, G., Thomas, X., Ffrench, M., & Marie, J. P. (1996). Timed sequential chemotherapy for advanced acute myeloid leukemia. Hematology and Cell Therapy. https://doi.org/10.1007/s00282-996-0161-2

Vancouver

Archimbaud E, Leblond V, Fenaux P, Dombret H, Cordonnier C, Dreyfus F, et al. Timed sequential chemotherapy for advanced acute myeloid leukemia. Hematology and Cell Therapy. 1996. doi:10.1007/s00282-996-0161-2

BibTeX
@article{Archimbaud1996,
  author = {Archimbaud, E and Leblond, V and Fenaux, P and Dombret, H and Cordonnier, C and Dreyfus, F and Cony-Makhoul, P and Tilly, H and Troussard, X and Auzanneau, G and Thomas, X and Ffrench, M and Marie, J P},
  title = {Timed sequential chemotherapy for advanced acute myeloid leukemia},
  journal = {Hematology and Cell Therapy},
  year = {1996},
  doi = {10.1007/s00282-996-0161-2}
}
Kostenlos starten →